Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 7/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | FLT1 | P17948 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131490 | 0.78 | GSK3B (0.48) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| SCHEMBL7739239 | 0.76 | CDC7 (0.48) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| SCHEMBL7737558 | 0.76 | KDR (0.47) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| SCHEMBL7460271 | 0.76 | CDC7 (0.46) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| Hydrochloric Acid SCHEMBL9960799 | 0.75 | CDC7 (0.46) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| SCHEMBL4983663 | 0.74 | KDR (0.54) | MAPK1ADRA2CKDRFLT1ABL1 | |
| SCHEMBL27647936 | 0.74 | POLB (0.45) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| SCHEMBL3714023 | 0.73 | CD38 (0.50) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| SCHEMBL5694501 | 0.73 | ROCK2 (0.47) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| SCHEMBL7738450 | 0.73 | RET (0.55) | CDC7ROCK2MAP4K4GSK3BCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | CDC7 3304/4885ROCK2 1178/4885MAP4K4 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.